Want to see FBLG full AI Analyst Report?
Top Page
FibroBiologics, Inc.
(NASDAQ:FBLG)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.75
▲(5.77% Upside)
Action:Downgraded
Date:08/01/26
The score is driven down primarily by weak financial performance (no revenue, sizable losses, and ongoing cash burn) and bearish technicals (trading below all major moving averages). Corporate events add notable risk due to impending Nasdaq delisting proceedings, partially offset by recent financing that improves near-term liquidity.
Positive Factors
Improved balance sheet and lower leverage
Material reduction in leverage and absolute debt strengthens financial resilience and lengthens runway versus prior years. A stronger capitalization profile reduces insolvency risk, improves bargaining power with partners and investors, and supports continued R&D investment over the coming quarters.
Negative Factors
Persistent negative operating cash flow
Sustained and large negative operating cash flow indicates the company burns material cash to fund R&D with no internal cash generation. Over a multi-month horizon this necessitates recurring external financing, increasing dilution risk and pressure on strategic flexibility if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet and lower leverage
Material reduction in leverage and absolute debt strengthens financial resilience and lengthens runway versus prior years. A stronger capitalization profile reduces insolvency risk, improves bargaining power with partners and investors, and supports continued R&D investment over the coming quarters.
Read all positive factors
FibroBiologics, Inc. (FBLG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.26M
Dividend YieldN/A
Average Volume (3M)978.93K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue GrowthN/A
EPS Growth22.10%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.57
Shares Outstanding6,080,560
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
FibroBiologics, Inc. Business Overview & Revenue Model
Company Description
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to addre...
How the Company Makes Money
null...
FibroBiologics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -234.00K | -832.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.14M | -17.61M | -10.57M | -15.90M | -4.37M | -1.58M |
| Net Income | -18.14M | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 7.93M | 9.62M | 16.45M | 11.82M | 4.82M | 468.00K |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 4.89M | 13.98M | 9.16M | 2.27M | 407.00K |
| Total Debt | 1.34M | 2.41M | 10.55M | 1.75M | 7.52M | 1.30M |
| Total Liabilities | 3.29M | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M |
| Stockholders Equity | 4.64M | 6.16M | 2.73M | 1.25M | -4.00M | -1.29M |
Cash Flow | ||||||
| Free Cash Flow | -14.80M | -16.66M | -12.09M | -6.90M | -4.07M | -1.41M |
| Operating Cash Flow | -14.79M | -16.39M | -11.90M | -6.40M | -4.07M | -1.41M |
| Investing Cash Flow | -6.00K | -262.00K | -184.00K | -495.00K | 0.00 | 0.00 |
| Financing Cash Flow | 9.47M | 7.57M | 16.91M | 13.79M | 5.92M | 1.82M |
FibroBiologics, Inc. Technical Analysis
Neutral
0.71
Price Trends
0.87
Negative
1.58
Negative
3.98
Negative
Market Momentum
-0.05
Negative
52.09
Neutral
68.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Neutral. The current price of 0.71 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.87, and below the 200-day MA of 3.98, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 52.09 is Neutral, neither overbought nor oversold. The STOCH value of 68.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FBLG.
FibroBiologics, Inc. Risk Analysis
FibroBiologics, Inc. disclosed 65 risk factors in its most recent earnings report. FibroBiologics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FibroBiologics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.69M | -1.46 | -47.86% | ― | -93.71% | 23.89% | |
47 Neutral | $14.04M | -22.68 | -5.42% | ― | ― | -138.25% | |
44 Neutral | $9.78M | -0.21 | 805.67% | ― | -36.95% | 80.84% | |
44 Neutral | $5.95M | -0.20 | -281.30% | ― | ― | 86.07% | |
40 Underperform | $4.26M | -0.11 | -767.07% | ― | ― | 22.10% |
* Healthcare Sector Average
FBLG
FibroBiologics, Inc.
0.82
-10.28
-92.60%
BLRX
Bioline RX Ltd Sponsored ADR
2.76
-1.13
-29.05%
CRIS
Curis
4.72
-28.68
-85.87%
SYBX
Synlogic
1.18
-0.22
-15.71%
LEXX
Lexaria Bioscience
5.62
-7.58
-57.42%
PCSA
Processa Pharmaceuticals
2.12
-3.93
-64.96%
FibroBiologics, Inc. Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
FibroBiologics Faces Nasdaq Delisting, Appeals Planned
Negative
Jul 24, 2026
On July 22, 2026, FibroBiologics, Inc. received a Staff Determination letter from Nasdaq stating that its securities are subject to delisting from The Nasdaq Capital Market because the company’s bid price closed below $1.00 per share for 30 ...
Executive/Board Changes
FibroBiologics Appoints NASA Scientist Kate Rubins to Board
Positive
Jul 9, 2026
On July 2, 2026, FibroBiologics director Matt Link resigned from the company’s board, and on July 8, 2026, the board appointed microbiologist and retired NASA astronaut Kathleen “Kate” Rubins, Ph.D., as a Class III director with ...
Business Operations and StrategyPrivate Placements and Financing
FibroBiologics Secures New Private Placement Financing
Positive
Jun 29, 2026
On June 25, 2026, FibroBiologics, Inc. entered into a securities purchase agreement for an at-the-market private placement with an accredited investor that generated $3 million in gross proceeds and approximately $2.6 million in net proceeds after...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
FibroBiologics Shareholders Approve New 2026 Equity Plan
Positive
Jun 23, 2026
FibroBiologics, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders approved a new 2026 Equity and Incentive Compensation Plan to replace the 2022 Stock Plan, authorizing 2,061,968 shares for awards and adding an...
Private Placements and FinancingRegulatory Filings and Compliance
FibroBiologics Expands At-The-Market Equity Offering Capacity
Neutral
May 6, 2026
FibroBiologics, Inc. disclosed that on May 1, 2026 it entered into an At The Market Offering Agreement with H.C. Wainwright Co. under which it may issue and sell common stock from time to time pursuant to an existing shelf registration. The ATM O...
Executive/Board Changes
FibroBiologics Grants Stock Options to Key Executives
Neutral
May 5, 2026
On May 4, 2026, FibroBiologics, Inc.’s compensation committee granted stock options under its 2022 Stock Plan to senior executives, including options to purchase 92,410 shares to Chief Executive Officer Pete O’Heeron and 61,607 shares ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.